, ?lng=FR&data_id=703&Disease_Disease_Search_di seaseGroup=behcet&Disease_Disease_Search_diseaseType=Pat&Maladie(s )/groupes%20de%20maladies=Maladie-de-Behcet&title=Maladie-de-Behcet&search=Disease_Search_Simple, Maladie de Behcet

. Aouba-a, Maladie de Behçet : Vascularites, Rev Prat, vol.58, issue.5, pp.533-573, 2008.

F. Benezra-d, N. Jv, . Rb, . Tabbara-k, and . Timonen-p, Uveitis scoring system, Uveitis Scoring System

. Khairallah-m, . Accorinti-m, . Muccioli-c, K. Kahloun-r, and . Jh, Epidemiology of Behçet Disease, Ocul Immunol Inflamm, vol.20, issue.5, pp.324-359, 2012.

M. A. Chamberlain, A family study of Behcet's syndrome. Ann Rheum Dis, vol.37, pp.459-65, 1978.

. Dalvi-sr and Y. Yildirim-r, Behcet's Syndrome, Drugs. 3 déc, vol.72, issue.17, pp.2223-2264, 2012.

, Orphanet: À propos des maladies rares

. Cho, . Sb, . Cho-s, and . Bang-d, New Insights in the Clinical Understanding of Behçet's Disease, Yonsei Med J. 1 janv, vol.53, issue.1, pp.35-42, 2012.

. Altenburg-a, . Papoutsis-n, H. Orawa, P. Martus, Z. Krause-l et al., Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany -current pathogenetic concepts and therapeutic possibilities, J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. janv, vol.4, issue.1, pp.49-64, 2006.

A. Lm, P. Sr, and P. Twj, Behçet's disease: a review, J Dent Res. mars, vol.84, issue.3, pp.209-231, 2005.

. Yurkadul-s and . Yazici-y, Epidemiology of Behçet's Syndrome and Regional Differences in Disease Expression, Yaz?c? Y, Yaz?c? H, éditeurs. Behçet's Syndrome

D. Sur,

C. Davatchi-f, H. Shams, . Nadji-a, . Faezi-t, and . Akhlaghi-m, Adult Behcet's disease in Iran: analysis of 6075 patients, Int J Rheum Dis. août, 2015.

. Wozniacka-a, . Jurowski-p, . Omulecki-a, and D. Kot-m, Behçet's disease leaves the silk road, Adv Dermatol Allergol, vol.6, pp.417-437, 2014.

. Saadoun-d and . Wechsler-b, Behçet's disease, Orphanet J Rare Dis, vol.7, issue.1, p.20, 2012.

. Rajendran-a and . Sundaram-s, Shafer's Textbook of Oral Pathology, vol.1001, 2014.

. Gabay-c.-syndrome-de and . Behçet, Rev Med Suisse, pp.728-761, 2008.

. Bodaghi-b, D. Wechsler-b, C. Lth, . Lehoang-p, and . Piette-j-c, Chronic severe uveitis: classification, search for etiology and therapeutic approach. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, déc, vol.24, issue.12, pp.794-802, 2003.

, Haute-vision

D. Sur,

C. , L. , and T. Huang-d-f, Behcet's Disease with Uveitis in Taiwan, J Chin Med Assoc, vol.71, issue.10, pp.509-525, 2008.

S. Merashli-m, A. Ic, and . Prj, Subclinical atherosclerosis in Behcet's disease: A systematic review and meta-analysis, Semin Arthritis Rheum Fev, vol.45, issue.4, pp.502-512, 2016.

. Demirelli-s, H. Degirmenci, and I. S. Arisoy-a, Cardiac manifestations in Behcet disease, Intractable Rare Dis Res, vol.4, issue.2, pp.70-75, 2015.

. Skef-w, Gastrointestinal Behçet's disease: A review, World J Gastroenterol, vol.21, issue.13, p.3801, 2015.

. Mendes-d, . Correia-m, . Barbedo-m, . Vaio-t, . Mota-m et al., Behçet's disease -a contemporary review, J Autoimmun. mai, vol.32, issue.3-4, pp.178-88, 2009.

. Tunes-r and . Santiago-m, Behcets Syndrome: Literature Review, Curr Rheumatol Rev. 1 févr, vol.5, issue.1, pp.64-82, 2009.

. Scherrer-mar, R. Castro-lpf, . Vb, and . Pacheco-l, The dermatoscopy in the skin pathergy testing: case series in patients with suspected Behçet's Disease. Rev Bras Reumatol Engl Ed, vol.54, pp.494-502, 2014.

. Varol-a, O. Seifert, and A. C. , Innate Immune System of Skin and Oral Mucosa : Properties and Impact in Pharmaceutics, Cosmectifs and Personal Care Products, Arch Dermatol Res, vol.155, p.p, 2010.

. Hatemi-g, . Silman-a, . Bang-d, . Bodaghi-b, . Chamberlain-am et al., EULAR recommendations for the management of Behcet disease, Ann Rheum Dis. 1 déc, vol.67, issue.12, pp.1656-62, 2008.

B. Lawton-g, C. Bb, . Ma, and . Tennant-a, The Behcet's disease activity index, Rheumatol Oxf Engl. janv, vol.43, issue.1, pp.73-81, 2004.

. Mumcu-g, Y. Yazici, and C. Ma, Disease Assessment in Behçet's Disease, Yaz?c? Y, Yaz?c? H, éditeurs. Behçet's Syndrome

M. Melikoglu-m and . Ma, What affects the quality of life in patients with Behcet's disease?, Acta Reumatol Port. mars, vol.39, issue.1, pp.46-53, 2014.

Y. Ishigatsubo, Behçet's Disease: From Genetics to Therapies, vol.183, 2014.

. Kaburaki-t, . Namba-k, . Sonoda-k, . Kezuka-t, and . Keino-h, Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab, Jpn J Ophthalmol. mars, vol.58, issue.2, pp.120-150, 2014.

, Eye and Behçet new therapeutics perspective

. Biologie,

. Cambier-l, . Defaweux-v, . Baldo-a, . Mathy-a, J. Tabart et al., Rôle des cellules Th17 dans les maladies infectieuses et auto-immunes, Ann. Méd. Vét, pp.104-116, 2010.

N. A. Sy, P. , and P. S. Lee-e-s, Up-regulation of Th17 and related cytokines in Behçet's disease corresponding to disease activity, Clin Exp Rheumatol. juin, vol.31, issue.3, pp.32-40, 2013.

P. Uc, K. Tw, and Y. U. Hg, Immunopathogenesis of Ocular Behçet's Disease, J Immunol Res, vol.2014, pp.1-13, 2014.

H. Le-système,

L. De-menthon-m, . Mp, . Maldini-c, . Guillevin-l, and . Mahr-a, HLA-B51/B5 and the risk of Behçet's disease: A systematic review and metaanalysis of case-control genetic association studies, Arthritis Rheum, vol.61, issue.10, pp.1287-96, 2009.

C. L. Caso-f, L. Rigante-d, . Om, . Caso-p, and . Bascherini-v, Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy, Mediators Inflamm, vol.2014, pp.1-14, 2014.

. Bouchra-a, Les manifestations ophtalmologiques au cours de la maladie de Behçet ( à propos de 33 cas). Faculté de Médecine de Fès, 2011.

. Tursen-Ü, Pathophysiology of the Behçet's Disease, Pathol Res Int, vol.2012, pp.1-11, 2012.

. Alexoudi-i, . Kapsimali-v, . Vaiopoulos-a, . Kanakis-m, and . Vaiopoulos-g, Evaluation of current therapeutic strategies in Behçet's disease, Clin Rheumatol. févr, vol.30, issue.2, pp.157-63, 2011.

. Greaves-mw, Anti-inflammatory action of corticosteroids, Postgrad Med J. oct, vol.52, issue.612, pp.631-634, 1976.

. Mesquida-m, . Molins-b, H. Llorenc-v, . Mv, G. Espinosa et al., Current and future treatments for Behçet's uveitis: road to remission, Int Ophthalmol. avr, vol.34, issue.2, pp.365-81, 2014.

. Yazici-h, H. Pazarli, . Barnes-cg, Y. Tuzun, Y. Ozyazgan et al., A controlled trial of azathioprine in Behçet's syndrome, N Engl J Med. 1 févr, vol.322, issue.5, pp.281-286, 1990.

A. Zierhut-m, . El-asrar-am, and T. Bodaghi-b, Therapy of ocular Behçet disease, Ocul Immunol Inflamm. févr, vol.22, issue.1, pp.64-76, 2014.

. Bang-b, Treatment of Behcet's Disease, Yonsei Med J, vol.38, issue.6, pp.401-411, 1997.

, Résumé des Caractéristiques du Produit PROGRAF

, Notice patient AZATHIOPRINE, p.51

. Yoo, . Sk, . Starnes-tw, . Deng-q, and . Huttenlocher-a, Lyn is a redox sensor that mediates leukocyte wound attraction in vivo, Nature, vol.480, issue.7375, pp.109-121, 2011.

. Hatemi-g, . Seyahi-e, . Fresko-i, . Talarico-r, and . Hamuryudan-v, Behçet's syndrome: a critical digest of the 2013-2014 literature, Clin Exp Rheumatol. août, vol.32, issue.4, pp.112-122, 2014.

, Notice patient COLCHICINE

. Warwick-gp, THE MECHANISM OF ACTION OF ALKYLATING AGENTS, Cancer Res. sept, vol.23, pp.1315-1348, 1963.

. Weill-b and . Batteux-f, Immunopathologie et réactions inflammatoires, vol.316, 2003.

. Smith-e and . Yazici-y, Treatment of Behçet's syndrom. Peter A merkel, 2009.

S. Becker-md, M. R. Jr, and . Fiehn-c, Management of sight-threatening uveitis: new therapeutic options, Drugs, vol.65, issue.4, pp.497-519, 2005.

C. Evereklioglu, Current concepts in the etiology and treatment of Behçet disease, Surv Ophthalmol. août, vol.50, issue.4, pp.297-350, 2005.

P. Aj and . Hsu-s, A review of thalidomide's history and current dermatological applications, Dermatol Online J. août, vol.9, issue.3, p.5, 2003.

, Autorité de Santé adoptant la recommandation relative à la prise en charge à titre dérogatoire du thalidomide (THALIDOMIDE CELGENE 50 mg, gélule) dans le cadre d'une recommandation temporaire d'utilisation, Haute Autorité de Santé -DECISION N° 2015.0155/DC/SEM du 17 juin 2015 du collège de la Haute

. Hamuryudan-v, . Mat-c, . Saip-s, Y. Ozyazgan, . Siva-a et al., Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial, Ann Intern Med. 15 mars, vol.128, issue.6, pp.443-50, 1998.

I. La-mémoire,

. Welschof-m and . Krauss-j, Recombinant antibodies for cancer therapy: methods and protocols, Methods in molecular biology, vol.481, 2003.

A. El-asrar-a, Behçet disease, sarcoidosis, VKH, Acta Ophthalmol (Copenh). sept, vol.90, pp.0-0, 2012.

. Choi-b, K. Hwang-y, . Hj, P. Lee-e-s, . Ks et al., Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model, J Dermatol Sci, vol.52, issue.2, pp.87-97, 2008.

. Arnaud-l, J. Haroche, and A. Piette-j-c, Les biothérapies immunomodulatrices du futur : quelles perspectives ? Presse Médicale, vol.38, pp.749-60, 2009.

. Arida-a, G. E. Fragiadaki-k, and S. Pp, Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 Patients, Semin Arthritis Rheum. août, vol.41, issue.1, pp.61-70, 2011.

G. Diaz-llopis-m, . Salom-d, . Udaonodo-p, . Hernandez-garfella-m, and . Bosch-morell-f, Adalimumab therapy for refractory uveitis: a pilot study, J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. juin, vol.24, issue.3, pp.351-61, 2008.

. Hamam-rn, A. Barikian-aw, A. Rs, A. Mr, . Rm et al., Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study, Ocul Immunol Inflamm. 24 août, pp.1-8, 2015.

. Ahmadi-m and . Khalili-h, Potential benefits of pentoxifylline on wound healing, Expert Rev Clin Pharmacol. janv, vol.9, issue.1, pp.129-171, 2016.

. Muller-b, . Komas-n, . Keravis-t, and . Lugnier-c, les phosphodiestérases des nucléotides cycliques, MédecineSciences. déc, vol.9, issue.12, 1993.

Z. Alpsoy-e, E. Cc, and . Ge, Mucocutaneous Lesions of Behçet's Disease, Yonsei Med J, vol.48, issue.4, p.573, 2007.

Y. Fn and . Uzun-a, Results of interferon alpha-2a therapy in patients with Behcet's disease, J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. août, vol.28, issue.4, pp.439-482, 2012.

, Iridotomie laser et glaucome

. Galeone-m, E. Colucci-r, . Am, and L. T. Moretti-s, Potential Infectious Etiology of Behçet Disease, Potential Infectious Etiology of Behçet Disease, Pathol Res Int Pathol Res Int. 29 déc, p.595380, 2011.

, Code de la santé publique -Article L1121-1, 2016.

, LEEM. Les grandes étapes de la vie d'un médicament

, Etudes cliniques, 20 questions, p.81

, Sanofi -Essais cliniques : les phases

L. Code-de-nuremberg,

, pdf/d29861b8-30a7-456e-9a83-508f14f4e6d5

, WMA Declaration of Helsinki -Ethical Principles for Medical Research Involving Human Subjects

, Les bonnes pratiques cliniques: directives consolidées

, Lignes directrices relatives aux Bonnes Pratiques Cliniques (BPC) pour l'essai des médicaments

, ClinicalTrials -Abatacept in the Treatment of Uveitis

-. Clinicaltrials, Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome

. Clinicaltrials--intravitreal, Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study

, ClinicalTrials -Anakinra for Behcet's Disease

, Anakinra for resistant Behçet uveitis: why not?

. Clinicaltrials--efficacy, . Safety, and . Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody

, ClinicalTrials -Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions

. Gul-a, D. Tugal-tutkun-i, . Ca, E. Reznikov-l, . Ba et al., Interleukin-1 -regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study, Ann Rheum Dis. 1 avr, vol.71, issue.4, pp.563-569, 2012.

-. Clinicaltrials, Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease, 2016.

. Xoma--xoma, Announces Results From Phase 3 EYEGUARD(TM)-B Study, 2016.

E. Xoma--gevokizumab-behcets, , 2016.

, ClinicalTrials -Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD TM -B), 2016.

, Public summary of opinion on orphan designation Recombinant human monoclonal antibody to human interleukin (IL)-17A of the IgG1/k class for the treatment of chronic non-infectious uveitis, 2016.

T. Dick-ad, F. S. Zierhut-m, M. Liew-sh, and . Bezlyak-v, Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials. Ophthalmology. avr, vol.120, issue.4, pp.777-87, 2013.

P. Ramsden-cm, C. Mb, S. Mjk, D. A. Cruz-l, and C. Pj, STem cells in retinal regeneration: past, present and future, Development. 15 juin, vol.140, issue.12, pp.2576-85, 2013.

. Davtachi-f, . Nikbin-b, H. Shams, . Sadeghi-abdollahi-b, . Mohyeddin-m et al., Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet's disease retinal vasculitis: report of three patients, Int J Rheum Dis. avr, vol.16, issue.2, pp.139-186, 2013.

. Kicic-a, W. Shen-w-y, C. As, . Ij, R. Robertson-t et al., Differentiation of marrow stromal cells into photoreceptors in the rat eye, J Neurosci Off J Soc Neurosci. 27 août, vol.23, issue.21, pp.7742-7751, 2003.

. Règlement, du parlement européen et du conseil du 16 décembre 1999 concernant les médicaments orphelins, 2000.

. Heemstra, . He, B. Van-weely-s, L. Ha, D. E. Hgm et al., Translation of rare disease research into orphan drug development: disease matters, Drug Discov Today. déc, vol.14, pp.1166-73, 2009.

L. Van-der, W. Jh, T. Mwt, and . Offringa-m, Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases, J Clin Epidemiol. avr, vol.61, issue.4, pp.324-354, 2008.

, Méthodologie des essais cliniques de petits effectifs

, Patient's recruitment in clinical trials for rare diseases a strategy to anticipate, vol.108